Direct Compression Envelopes for Chlorpromazine Hydrochloride in Canine Antiemetic Tablets

Chlorpromazine veterinary grade API is formulated into immediate-release tablets for canine antiemetic use as the hydrochloride salt, with finished strengths of 5 mg, 10 mg, 25 mg, 50 mg, and 100 mg. The formulation addition ratio is constrained by the poor flow and high electrostatic tendency of the crystalline API. At API loads below 15% w/w, direct compression is feasible on 8 mm round tooling, but production-scale runs above this threshold are shifted to dry granulation because capping occurs at compression forces exceeding 14 kN when microcrystalline cellulose is below 20% w/w. A representative core formula uses 25 mg chlorpromazine hydrochloride in a total core weight of 180–220 mg, equivalent to 11.4–13.9% w/w, with lactose monohydrate at 45–65% w/w, microcrystalline cellulose at 20–30% w/w, crospovidone at 2–5% w/w, and magnesium stearate at 0.5–1.0% w/w. The dry granulation step uses a roller compactor at 4–7 MPa roll pressure and a 0.8 mm or 1.2 mm oscillating screen, followed by V-blender lubrication at 20 rpm for 10 min. Tablet compression is performed on a 16-station rotary press at 45 rpm with 10–16 kN force and 50–80 N average hardness; friability remains below 0.8% and disintegration below 15 minutes. Dissolution is tested using USP Apparatus 2 at 50 rpm in 0.1 N hydrochloric acid and pH 4.5 buffer, with Q ≥ 75% release at 30 minutes. Pre-drying of the roller-compacted granules is required when ambient relative humidity exceeds 60%, and final blend LOD is held below 2.0% before compression to prevent picking on punch faces. Industry compliance standards include USP-NF Chlorpromazine Hydrochloride Tablets monograph, USP <905>, USP <1217>, USP <711>, Ph. Eur. 2.9.5, Ph. Eur. 2.9.7, ICH Q3B, ICH Q3D, VICH GL18, and 21 CFR 211. Terminal finished products are amber blister strips and HDPE bottles with desiccant, because the API is photosensitive and oxidatively labile in prolonged storage.

Aqueous injectable chlorpromazine hydrochloride at 2.5% w/v (25 mg/mL) is manufactured for preanesthetic sedation and antiemetic support in small animal emergency and surgical services. The formulation addition ratio is fixed around 2.3–2.7% w/v because precipitation of the free base occurs above pH 5.5, while oxidative discoloration accelerates below pH 3.0 in the presence of dissolved oxygen. The bulk solution is prepared with chlorpromazine hydrochloride at 2.5% w/v, sodium chloride at 0.9% w/v, sodium metabisulfite at 0.1% w/v, and citrate buffer to pH 3.8–4.5, with nitrogen sparging at 1–2 L/min per 100 L batch volume. Downstream production uses 0.22 µm PVDF clarification and sterilizing-grade filtration in a closed aseptic filling line; terminal steam sterilisation at 121 °C for 15 min is avoided because thermal oxidation shifts the solution beyond compendial color limits within 3–6 months at 25 °C. Filled units are amber glass ampoules and multi-dose vials with nitrogen headspace. Compliance testing includes USP <1>, USP <71>, USP <85>, USP <788>, Ph. Eur. 2.6.1, Ph. Eur. 2.6.14, Ph. Eur. 2.9.19, Ph. Eur. 5.1.1, ICH Q3D, and EU GMP Annex 1. Terminal finished products are 25 mg/mL injections in 1 mL, 2 mL, 10 mL, and 30 mL presentations.

Multi-dose vial development requires glass-to-stopper compatibility testing because chlorpromazine hydrochloride can mobilize certain elastomeric antioxidants. On production lines, headspace oxygen is held below 2.0% v/v, and filling is conducted under filtered nitrogen. Published stability data for 30 mL multi-dose presentations at 40 °C/75% RH is limited; real-time stability at 25 °C is therefore required to establish shelf-life.

Why Does Granule Densification Determine Weight Uniformity in Chlorpromazine Hydrochloride Capsules?

Hard gelatin and hydroxypropyl methylcellulose capsules for companion animal dose titration are produced with chlorpromazine hydrochloride strengths of 5 mg, 10 mg, 25 mg, and 50 mg. The formulation addition ratio ranges from 8–60% w/w, but direct powder filling is stopped above 30% w/w because the API’s high electrostatic charge and low bulk density cause segregation and weight variability beyond ±5% on dosator capsule machines. The downstream process therefore includes slugging or roller compaction to densify the powder; target tap density is 0.55–0.70 g/mL with a Carr index of 15–20%. After compaction at 12–20 kN and screening through a 1.0 mm sieve, the densified material is blended with lactose monohydrate, pregelatinized starch, and magnesium stearate at 0.5% w/w for 5 min in a low-shear tumble blender. Slugging is preferred over aqueous wet granulation because the hydrochloride salt dissolves in granulating fluid and forms sticky masses that increase drying time and impurity formation. Capsule filling runs at 20,000 capsules/h on a dosator-type machine with relative humidity below 45% and temperature at 18–22 °C; moisture uptake above this threshold softens gelatin shells and accelerates sulfoxide formation. Dissolution is tested with USP Apparatus 1 at 100 rpm in 0.1 N hydrochloric acid, with Q ≥ 75% at 30 minutes. Industry compliance standards include USP-NF Chlorpromazine Hydrochloride Capsules monograph, USP <1174>, USP <711>, USP <801>, Ph. Eur. 2.9.5, ICH Q3B, and ICH Q3D. Terminal finished products are immediate-release hard gelatin or HPMC capsules in amber glass bottles and cold-sealed blister packaging.

Oral solutions containing chlorpromazine hydrochloride at 5 mg/mL and 25 mg/mL for feline and canine dose titration are buffered below pH 5.0 to maintain solubility and chemical stability. The free base has a pKa of approximately 9.3; at pH values above 6.5, precipitation occurs, so alkaline buffering agents are incompatible. The formulation addition ratio is 0.5–2.5% w/v chlorpromazine hydrochloride, with sodium metabisulfite at 0.05–0.1% w/v, sodium chloride at 0.1–0.5% w/v, and a citrate or acetate buffer at pH 3.8–4.5, made to volume with purified water. The compounding process uses nitrogen sparging during mixing, followed by 0.45 µm filtration and filling into 30 mL or 100 mL amber Type III glass bottles with child-resistant closures and graduated oral dosing syringes. Light protection is mandatory because aqueous solutions of chlorpromazine develop pink-to-violet degradation products upon prolonged exposure. Sulfur dioxide labelling is required in markets where sulfite sensitization is a recognized concern. Compliance anchors include USP-NF Chlorpromazine Hydrochloride Oral Solution monograph, USP <795> for extemporaneous compounding where applicable, USP <911>, ICH Q1A, ICH Q3B, ICH Q3D, and 21 CFR 211. Terminal finished products are oral solutions at 5 mg/mL and 25 mg/mL for dogs and cats, with dose titration provided by graduated droppers or syringes.

When Chlorpromazine Hydrochloride Is Granulated for Oral Syringe Delivery, Sieve Retention and Friability Shift Together

Wet granulation of chlorpromazine hydrochloride into oral granules for hospital dispensing is performed when tablet splitting is unsuitable for low-bodyweight or non-food equine patients. The formulation addition ratio in the final granules is 1–20% w/w, equivalent to 10 mg/g to 200 mg/g depending on the intended dilution vehicle. A typical batch uses chlorpromazine hydrochloride at 2.5–10.0% w/w, lactose monohydrate or mannitol at 70–90% w/w, povidone K30 binder at 3–5% w/w, and purified water as granulating fluid. The downstream production process uses a high-shear mixer with chopper at 1500 rpm, followed by fluid-bed drying at inlet 60 °C and product temperature not exceeding 50 °C; the drying endpoint is LOD below 2.0%. Sieving through 500–1000 µm screens and re-blending of oversize material is required because the API particle-size distribution shifts during high-shear exposure and changes syringe dispersibility. In-process sieving controls the shift toward fines when chopper time exceeds 10 minutes. Friability assessed by Ph. Eur. 2.9.12 is controlled by the binder level and granule moisture; lower binder content raises fines and causes poor dose uniformity in unit-dose sachets. Industry compliance standards include USP <1174>, USP <786>, Ph. Eur. 2.9.12, VICH GL18, and ICH Q3B. Terminal finished products are unit-dose sachets, powder cups, and granules for oral suspension, dispensed with 1 mL or 3 mL oral syringes for dogs, cats, and non-food equine patients.

Premix Homogeneity Limits and Non-Food Species Labeling Boundaries

Chlorpromazine hydrochloride premix systems are manufactured as dry carrier blends for subsequent dilution in pharmaceutically acceptable vehicles, oral pastes, or hospital medicated feeds for non-food species. The formulation addition ratio is typically 1–5% w/w API on lactose monohydrate or dextrose carrier, with a final dilution to 0.5–2.0% w/w in ready-to-dose oral vehicles. Because chlorpromazine is a neuroleptic phenothiazine, premix blends are not intended for food-producing animals, and any equine use requires a valid food chain exclusion declaration where horses may be classified as food animals. The downstream process uses geometric dilution in a 50–500 kg ribbon blender at 15–20 rpm for 15–20 min, followed by 1.2 mm sieving to remove agglomerates. Blend uniformity is assessed at 10 sampling points with CV ≤ 5%; published data for chlorpromazine premix homogeneity in zoological feed matrices is limited, so batch-scale uniformity studies are normally required before release. Near-infrared chemical imaging is used to verify blend homogeneity in tiered release programs to reduce thief-sampling bias. Industry compliance anchors include VICH GL18, ICH Q3B, ISO 22000, FAMI-QS where carried in the feed supply chain, and current Good Manufacturing Practice for veterinary medicinal products. Terminal finished products are 10 kg and 25 kg foil-lined drums of premix for institutional pharmacies and zoological formularies.